From Fortune:

Isomorphic Labs, a subsidiary of Alphabet Inc., has entered into research collaboration agreements with Novartis AG and Eli Lilly & Co. Under the partnership with Lilly, Isomorphic Labs will receive $45 million upfront and up to $1.7 billion in milestone payments for research into small molecule therapeutics. With Novartis, the company will receive $37.5 million upfront and up to $1.2 billion in milestone payments for research into small molecule therapeutics against undisclosed targets. Both partnerships aim to harness unique strengths to realize new possibilities in AI-driven drug discovery.



Read more: Alphabet’s Isomorphic labs to collaborate with Novartis, Lilly on AI-driven drug discovery